Ganglioglioma pathophysiology

Jump to navigation Jump to search

Ganglioglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Ganglioglioma from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ganglioglioma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ganglioglioma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onGanglioglioma pathophysiology

CDC on Ganglioglioma pathophysiology

Ganglioglioma pathophysiology in the news

on Ganglioglioma pathophysiology

Directions to Hospitals Treating Ganglioglioma

Risk calculators and risk factors for Ganglioglioma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

A ganglioglioma arises from neuronal glial cells, which are cells of the central nervous system. On gross pathology, a ganglioglioma varies from being a partially cystic mass with a mural nodule to a solid mass expanding the overlying gyrus. On microscopic pathology, a ganglioglioma is composed of ganglion cells and neoplastic glial cells with positive staining for synaptophysin, neuronal specific enolase, and GFAP.

Pathophysiology

Genetics

Mutation of BRAF V600E gene has been detected in ganglioglioma. The mutant BRAF protein is expressed predominantly in neural cells and to a lesser degree, in the glial component. [1] [2]

Pathogenesis

Different pathways may be involved in the molecular pathogenesis of the ganglioglioma. Activation of the PI3K-Akt-mTOR pathway has been noted in ganglioglioma.


Gross Pathology

Microscopic Pathology

Gangliogliomas are composed of two cell populations:[3]

  • Ganglion cells (large mature neuronal elements): ganglio-
  • Neoplastic glial elements (astrocytic): -glioma

The glial component determines the biological behaviour of ganglioglioma. Dedifferentiation into high grade tumors may occur, and usually involves the glial component.

Markers

References

  1. Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M; et al. (2013). "Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells". Acta Neuropathol. 125 (6): 891–900. doi:10.1007/s00401-013-1100-2. PMID 23435618.
  2. Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR (2013). "BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma". Acta Neuropathol. 125 (6): 901–10. doi:10.1007/s00401-013-1120-y. PMID 23609006.
  3. Pathophysiology of ganglioglioma. Dr Henry Knipe and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/ganglioglioma


Template:WikiDoc Sources